Dr. Kevin Bowling is a laboratory geneticist whose research focuses on using state of the art genomic technologies to diagnose rare disease in hopes of improving patient management and outcome. He holds a PhD in Molecular and Cellular Biology from the University of Alabama (2008) and completed postdoctoral training in human genetics at the HudsonAlpha Institute for Biotechnology (2009-2013). Dr. Bowling worked as a Senior Scientist at HudsonAlpha from 2013-2021 and is currently an Associate Professor in the Department of Pathology and Immunology at Washington University in St. Louis School of Medicine.

Previously, Dr. Bowling used a variety of molecular, biochemical, genetic, genomic, and bioinformatic approaches to identify and understand molecular alterations contributing to complex neurological phenotypes. As a senior scientist at HudsonAlpha, he used genome sequencing to genetically diagnose patients with rare disorders and to discover new disease-gene associations. He has also employed genotyping arrays to screen populations for risk of genetic disease, with focus on cancer and cardiovascular phenotypes. At Washington University School of Medicine, Dr. Bowling aids implementation of clinical genomic sequencing, improving/optimizing analysis and interpretation of genomic data, use of clinical genomic testing to diagnose rare disease and inform clinical decision-making, discovery of new-disease gene associations, and conducting clinical genetic testing to support clinical trials.

Dr. Bowling has participated in several large scientific consortia where he has led, or greatly contributed to, many different working groups. These include the Pritzker Neuropsychiatric Research Consortium, the Clinical Sequencing Exploratory Research Consortium, and the Alabama Genomic Health Initiative.